Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Who will be the the First to IPO: Novartis bought in to Intellia (UC, Berkeley) as well as Caribou (UC, Berkeley) vs Editas (MIT)??

Reporter: Aviva Lev-Ari, PhD, RN

Intellia

Editas

Editas Medicine is a transformative genome editing company founded by world leaders in the fields of genome editing, protein engineering, and molecular and structural biology, with specific expertise inCRISPR/Cas9 and TALENs technologies.

The company’s mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level. The company has generated substantial patent filings and has access to intellectual property covering foundational genome editing technologies, as well as essential advancements and enablements that will uniquely allow the company to translate early findings into viable human therapeutic products.

Editas was founded in 2013 with $43 million in Series A venture capital financing led by leading health care venture capital firms Flagship Ventures, Polaris Partners and Third Rock Ventures with participation from Partners Innovation Fund.

SOURCE

http://editasmedicine.com/about.php

Editas FOUNDERS

Editas Medicine’s academic founders are world leaders in the fields of genome editing, protein engineering, and molecular and structural biology, with specific expertise in CRISPR/Cas9 and TALENs technologies.

PUBLICATIONS

http://editasmedicine.com/publications.php

Selective List

M. Jinek, K. Chylinski, I. Fonfara, M. Hauer, J.A. Doudna, E. Charpentier. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 2012 Aug 17;337(6096):816-21. doi: 10.1126/science.1225829. Epub 2012 Jun 28

O. Niewoehner, M. Jinek, J.A. Doudna. Evolution of CRISPR RNA recognition and processing by Cas6 endonucleases. Nucleic Acids Res. 2013 Oct 22. Read More

V. Pattanayak, S. Lin,  J.P. Guilinger, E. Ma, J.A. Doudna, D.R. Liu. High-throughput profiling of off-target DNA cleavage reveals RNA-programmed Cas9 nuclease specificity. Nature Biotechnology. 2013 Aug 11. doi:10.1038/nbt.2673.

T. Lo, C.S. Pickle, S. Lin, E.J. Ralston, M. Gurling, C.M. Schartner, Q. Bian, J.A. Doudna, B.J. Meyer. Precise and Heritable Genome Editing in Evolutionarily Diverse Nematodes Using TALENs and CRISPR/Cas9 to Engineer Insertions and Deletions. Genetics. Advance online publication. 2013 Aug 9. doi:10.1534/genetics.113.155382. Read More

L.A. Gilbert, M. H. Larson, L. Morsut, Z. Liu, G.A. Brar, S.E. Torres, N. Stern-Ginossar, O. Brandman, E.H. Whitehead, J.A. Doudna, W.A. Lim, J.S. Weissman, L.S. Qi. CRISPR-Mediated Modular RNA-Guided Regulation of Transcription in Eukaryotes. Cell. 2013 July 11.10.1016/j.cell.2013.06.044. Read More

H.Y. Lee, R.E. Haurwitz, A. Apffel, K. Zhou, B. Smart, C.D. Wenger, S. Laderman, L. Bruhn, J.A. Doudna. RNA-protein analysis using a conditional CRISPR nuclease. Proc Natl Acad Sci U S A. 2013 Apr 2;110(14):5416-21. Read More

E. Charpentier, J.A. Doudna. Biotechnology: Rewriting a genome. Nature. 2013 Mar 7;495(7439):50-1. Read More

L.S. Qi, M.H. Larson, L.A. Gilbert, J.A. Doudna, J.S. Weissman, A.P. Arkin, W.A. Lim.Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression. Cell. 28 February 2013. 10.1016/j.cell.2013.02.022.Read More

M. Jinek, A. East, A. Cheng, S. Lin, E. Ma, J. Doudna. RNA-programmed genome editing in human cells. Elife. 2013;2:e00471. Read More

O’Connell, M.R., Oakes, B.L., Stmberg, S.H., East-Seletsky, A., Kaplan, M., and Doudna, J.A. Programmable RNA recognition and cleavage by CRISPR/Cas9. Nature, September 28, 2014. doi: 10.1038/nature13769. [E-pub ahead of print]   Read More

Jinek, M., Jiang, F.,Taylor, D.W., Sternberg, S.H., Kaya, E., Ma, E., Anders, C., Hauer, M., Zhou, K., Lin, S., Kaplan, M. Iavarone, A.T., Charpentier, E. Nogales, E., Doudna, J.A.Structures of Cas9 endonucleases reveal RNA-mediated conformational activation. Science, Feb. 6, 2014. DOI: 10.1126/science.1247997. [Epub ahead of print] Read More

Sternberg, S.H., Redding, S., Jinek, M., Greene, E.C., Doudna, J.A. DNA interrogation by the CRISPR RNA-guided endonuclease Cas9. Nature (2014) doi:10.1038/nature13011. [Epub ahead of print] Read More

CRISPR player Intellia looks IPO-ready after $70M round

 

 

Intellia’s John Leonard

Late last year, Atlas Venture joined hands with Novartis ($NVS) to launch gene-editing upstart Intellia and then swiftly followed up with a formal alliance to use CRISPR/Cas9 tech to fashion a new wave of therapeutics. Now, just 8 months after the pact, Intellia has gone back to the well, drawing up $70 million in cash from a group which includes some active crossover investors that have been instrumental in shepherding a flock of biotechs into the busy IPO market.

OrbiMed HealthCare Fund Management led the round, with help from Fidelity Management and Research Company, Janus Capital Management, Foresite Capital, Sectoral Asset Management, EcoR1 Capital and other unidentified leading investors. Founding investor Atlas Venture and Novartis also pitched in.

There are some things we do know about Intellia. Novartis bought in to Intellia–as well as Caribou, which out-licensed some pioneering CRISPR tech created by Jennifer Doudna at UC Berkeley–with a clear interest in tapping the science for its ambitious CAR-T work reengineering T cells into cancer weapons. John Leonard was wooed in from the Big Pharma world, after a stint in charge of R&D at AbbVie ($ABBV). And gene editing–deleting, repairing and inserting genetic information to correct an ailment–has what is widely viewed as a potent future in devising a new generation of potential cures.

“CRISPR/Cas9 technology has potential to transform medicine by addressing previously untreatable genetic targets and serving as the basis for new and better therapies,” said Leonard in a statement. “This novel technology could potentially eliminate many severely disabling and life-threatening diseases for patients.”

But after the Big Vision, detailed insights into the company’s plans can be hard to glean. Asked about the apparent likelihood of an IPO in the offing, CEO Nessan Bermingham declined comment.

Specific therapeutic programs? Not disclosed.

Timelines for getting into the clinic? That would be premature, says the CEO.

For a new, preclinical technology with a disputed provenance that pits Doudna and her CRISPR colleague Emmanuelle Charpentier in a challenge focused on patents held by rival Editas, which just raised its own $120 million crossover round, discretion appears to be the better part of valor in laying the foundation for a new company.

In the absence of any insights from Intellia, Editas would seem to be the closest to the clinic now. And all of the pioneers have enjoyed raising some jaw-dropping sums over the past year.

In the meantime, Bermingham says that a group of fewer than 40 staffers continues to grow. Just don’t ask them what they’re working on.

– here’s the release

Related Articles:
Novartis adopts a CRISPR-Cas9 partner and jumps into the hot new R&D field
A biotech war is brewing over control of the revolutionary CRISPR-Cas9 tech
Top research institutions hand hot gene-editing tech–with a catch–to Editas
Novartis joins Atlas in launching a CRISPR Cas biotech with a $15M bankroll

SOURCE

http://www.fiercebiotech.com/story/crispr-player-intellia-looks-ipo-ready-after-70m-round/2015-09-01?utm_medium=nl&utm_source=internal

From: FierceBiotech <editors@fiercebiotech.com>

Reply-To: <editors@fiercebiotech.com>

Date: Tuesday, September 1, 2015 at 12:26 PM

To: Aviva Lev-Ari <avivalev-ari@alum.berkeley.edu>

Subject: | 09.01.15 | Valeant-esque: AstraZeneca hives off brodalumab in $445M deal; Bristol-Myers, AbbVie speed ‘breakthrough’ drug to FDA

Other related articles on CRISPR Cas Technology published in this Open Access Online Scientific Journal include the following:

Where is the most promising avenue to success in Pharmaceuticals with CRISPR-Cas9?

Author: Larry H. Bernstein, MD, FCAP

http://pharmaceuticalintelligence.com/2015/09/01/where-is-the-most-promising-avenue-to-success-in-pharmaceuticals-with-crispr-cas9/

New Values for Capital Investment in Technology Disruption: Life Sciences Group @Google and the Future of the Rest of the Biotech Industry

Curator: Aviva Lev-Ari, PhD, RN

http://pharmaceuticalintelligence.com/2015/08/31/new-values-for-capital-investment-in-technology-disruption-life-sciences-group-google-and-the-future-of-the-rest-of-the-biotech-industry/

Level of Comfort with Making Changes to the DNA of an Organism

Curator: Aviva Lev-Ari, PhD, RN

http://pharmaceuticalintelligence.com/2015/08/30/level-of-comfort-with-making-changes-to-the-dna-of-an-organism/

Delineating a Role for CRISPR-Cas9 in Pharmaceutical Targeting

Author & Curator: Larry H. Bernstein, MD, FCAP

http://pharmaceuticalintelligence.com/2015/08/30/delineating-a-role-for-crispr-cas9-in-pharmaceutical-targeting/